

Title: Clinical Issues in Type 2 Diabetes Discussions and Debates Around GLP-1 Receptor Agonists

Dates: September 10, 2015 – September 10, 2016

Locations: <http://www.medscape.org/viewarticle/848124>

Learning Objectives:

- Describe the relative benefits and risks of GLP-1 receptor agonists versus other oral and injectable antidiabetes medications
- Select among available short- and long-acting GLP-1 receptor agonists when intensifying T2DM therapy for various patient types
- Tailor combination regimens that include GLP-1 receptor agonists and other antihyperglycemic agents based on disease severity, comorbidities, and risks of hypoglycemia
- Engage in open dialogues with patients about the clinical profiles of GLP-1 receptor agonists and treatment adherence

Target Audience: This activity was developed for endocrinologists and other health care providers involved in the treatment of patients with type 2 diabetes.

Program Overview: Over the past decade, increased understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) has aided in the development of new and expanding classes of antihyperglycemic medications. Agonists of glucagon-like peptide-1 (GLP-1) receptors, for example, take advantage of incretin hormone signaling to include glucose-independent insulin release from the pancreatic- β cells, reduce hepatic glucose production, slow gastric emptying, and increase satiety. The potential benefits and risks of GLP-1 receptor agonists for various patient types or complicating comorbidities are subject to ongoing clinical research. Indeed, education on how to achieve individualized glycemic targets and appropriately use these medications is of great practical interest to endocrinologists and other healthcare providers. This *Clinical Issues*[™] program will provide participants with significantly rigorous, clinically accurate, and highly applicable recommendations for the roles of GLP-1 receptor agonists in multimodal T2DM management.

Faculty:

Lawrence Blonde, MD, FACP, FACE, Moderator
Director, Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute,
Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana

Jamie A. Davidson, MD, FACP, MACE



Clinical Professor of Medicine, Touchstone Diabetes Center, University of Texas,
Southwestern Medical Center, Dallas, Texas

Daniel Einhorn, MD, FACP, FACE

Clinical Professor of Medicine, University of California San Diego, Diabetes and
Endocrine Associates, Medical Director, Scripps Whittier Diabetes Institute, La Jolla,
California

Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and Integritas. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement:

Clinical and Patient Educators Association designates this enduring activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support: This activity is supported by an independent educational grant from AstraZeneca.

